Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Jul 4, 2025

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source
08:35

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Published on: May 29, 2021

5.3K

利用专利数据的非活性增强型机器学习模型改善了基于结构的PDL1二元化器的虚拟选.

Pablo Gómez-Sacristán1, Saw Simeon1, Viet-Khoa Tran-Nguyen1

  • 1Centre de Recherche en Cancérologie de Marseille, Marseille 13009, France.

Journal of advanced research
|January 27, 2024
PubMed
概括
此摘要是机器生成的。

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Evaluation of Serum Adipocytokines and Cystatin C As Early Biomarkers in Chronic Kidney Disease Patients and Their Relation to Endothelial Dysfunction.

Cureus·2026
Same author

Decoding carbon, water, and energy exchange driven by agricultural and horticultural intensification in semi-arid ecosystem of India.

Environmental monitoring and assessment·2026
Same author

Successful Outcome of Rhino-Orbital-Cerebral Mucormycosis With Extensive Intracranial Disease in a Patient With Poorly Controlled Diabetes.

The Permanente journal·2026
Same author

Incidence and Outcomes of Metastatic Patterns of Pancreatic Ductal Adenocarcinoma.

The American surgeon·2025
Same author

Management of Hypertension and Associated Comorbidities: An Expert Consensus Statement from India.

The Journal of the Association of Physicians of India·2025
Same author

Computational modeling of protein-ligand interactions: From binding site identification to pose prediction and beyond.

Current opinion in structural biology·2025

针对PDL1二元化的机器学习评分函数 (SFs) 显示出开发新癌症药物的前景. 这些特定于PDL1的SF优于通用方法,有助于发现新型抑制剂.

科学领域:

  • 计算机化药物发现.
  • 在药理学中的机器学习.
  • 蛋白质 - 配体相互作用

背景情况:

  • 通过PDL1二元化向编程细胞死亡蛋白1/编程死亡连接体1 (PD1/PDL1) 提供了一条通往具有成本效益的癌症治疗的途径,改善了患者的治疗结果和减少了副作用.
  • 开发PDL1二分化剂一直是具有挑战性的,临床进展有限,突出显示了对高效药物发现方法的需求.

研究的目的:

  • 为了证明基于结构的虚拟选 (SBVS) 的实用性,采用PDL1特定的机器学习评分函数 (MLSFs) 来通过PDL1二分化识别PD1/PDL1抑制剂.
  • 建立MLSF作为药物设计中的一个强有力的工具,用于这个治疗目标.

主要方法:

  • 创建和评估众多PDL1特异性的MLSF,包括分类器和非活性丰富回归器.
  • 纳入最近在MLSF开发中的进展.
  • 验证使用两个严格的测试数据集来评估预测性能.

主要成果:

  • 成功生成了60个PDL1特定的MLSF (30个分类器,30个回归器).
  • 证明了包含众多停靠不活的大型训练数据集可以显著提高MLSF的性能.
  • 为开发的PDL1特定的MLSF实现了高度预测能力.
关键词:
人工智能的人工智能是人工智能.停靠对接 停靠对接免疫治疗是一种免疫疗法.机器学习是机器学习.这就是PD1 PD1.在 PDL1 中,PDL1 是 PDL1.虚拟选是一个虚拟的选.

更多相关视频

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.1K
Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

2.5K

相关实验视频

Last Updated: Jul 4, 2025

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source
08:35

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Published on: May 29, 2021

5.3K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.1K
Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

2.5K

结论:

  • 针对PDL1目标,PDL1特定的MLSF在各种类型中显著优于通用评分功能.
  • 开发的PDL1特异性MLSF无限制公开提供,以促进进一步的研究和药物开发.